^
Association details:
| Biomarker: | EGFR exon 19 deletion + NRAS Q61K |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | gefitinib (EGFR inhibitor) + Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib
Excerpt:
We established gefitinib resistant PC-9 cells which harbor EGFR exon 19 deletion....We observed heterozygous NRAS Q61K mutations in PC‐9/gef B4, PC‐9/gefE3, and PC‐9/gefE7 cells but not in the PC‐9/wt cell...Our in vivo studies showed that gefitinib inhibited growth of PC-9/wt xenografts but not PC-9/gef xenografts....In conclusion, persistent activation of the MAPK cascade possibly owing to NRAS mutation results in the acquired gefitinib resistance of lung adenocarcinoma harboring activation EGFR mutation...
DOI:
10.1016/j.molonc.2012.09.002
